

EL REUMATÓLOGO Nº 9

ARTÍCULO: EVIDENCIA CIENTÍFICA Y PREVENCIÓN DE LA APARICIÓN DE FRACTURAS TRAS LA SUSPENSIÓN DE DENOSUMAB

Javier del Pino Montes

M^a Elisa Acosta de la Vega

Hospital Universitario de Salamanca

BIBLIOGRAFÍA

1. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis for the FREEDOM Trial*. *N Engl J Med.* 2009;8361(20):756–65.
2. Uebelhart B, Rizzoli R, Ferrari SL. Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates. *Osteoporos Int [Internet].* 2017;28(9):2701–5.
3. Lyu H, Yoshida K, Zhao SS, Wei J, Zeng C, Tedeschi SK, et al. Delayed Denosumab Injections and Fracture Risk Among Patients With Osteoporosis : A Population-Based Cohort Study. *Ann Intern Med.* 2020;173(7):516–26.
4. Fernández Fernández E, Benavent Núñez D, Bonilla Hernán G, Monjo Henry I, García Carazo S, Bernad Pineda M, et al. Fracturas vertebrales múltiples tras la suspensión de tratamiento con denosumab: serie de diez casos. *Reumatol Clínica.* 2020;16(6):480–4.
5. Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen J-EB, McClung M, et al. Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. *J Bone Miner Res* 2018;33(2):190–8.
6. Tripto-Shkolnik L, Fund N, Rouach V, Chodick G, Shalev V, Goldshtein I. Fracture incidence after denosumab discontinuation: Real-world data from a large healthcare provider. *Bone.* 2020;130(October 2019):115150.
7. Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O. Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases. *J Bone Miner Res.* 2017 Jun;32(6):1291–6.
8. Gonzalez-Rodriguez E, Stoll D, Lamy O. Raloxifene Has No Efficacy in Reducing the High Bone Turnover and the Risk of Spontaneous Vertebral Fractures after Denosumab Discontinuation. *Case Rep Rheumatol.* 2018;2018:5432751.
9. Ebina K, Hashimoto J, Kashii M, Hirao M, Miyama A, Nakaya H, et al. Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis. *Mod Rheumatol.* 2020 Jun 8;1–8.
10. Tsourdi E, Zillikens MC, Meier C, Body J-J, Gonzalez Rodriguez E, Anastasilakis AD, et al. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. *J Clin Endocrinol Metab.* 2020; Available from: <http://www.ncbi.nlm.nih.gov/pubmed/33103722>
11. Freemantle N, Satram-Hoang S, Tang ET, Kaur P, MacArios D, Siddhanti S, et al. Final results of the DAPS (denosumab adherence preference satisfaction) study: A 24-month, randomized, crossover comparison with alendronate in postmenopausal women. *Osteoporos Int.* 2012;23(1):317–26.

El Reumatólogo

12. McClung MR, Wagman RB, Miller PD, Wang A, Lewiecki EM. Observations following discontinuation of long-term denosumab therapy. *Osteoporos Int.* 2017;28(5):1723–32. A
13. Leder BZ, Tsai JN, Jiang LA, Lee H. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up). *Bone.* 2017 May;98:54–8.
14. Laroche M, Couture G, Ruysen-Witrand A, Constantin A, Degboé Y. Effect of risedronate on bone loss at discontinuation of denosumab. *Bone reports.* 2020 Dec;13:100290.
15. Anastasilakis AD, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Makras P. Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial. *J Bone Miner Res.* 2019;34(12):2220–8.
16. Makras P, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Anastasilakis AD. The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis. *Bone.* 2020;138:115478.
17. Sølling AS, Harsløf T, Langdahl B. Treatment with Zoledronate Subsequent to Denosumab in Osteoporosis: a Randomized Trial. *J Bone Miner Res.* 2020 Oct;35(10):1858–70.
18. Naranjo Hernández A, Díaz Del Campo Fontecha P, Aguado Acín MP, Arboleya Rodríguez L, Casado Burgos E, Castañeda S, et al. Recommendations by the Spanish Society of Rheumatology on Osteoporosis. *Reumatol Clin.* 15(4):188–210.
19. Ferrari S, Libanati C, Lin CJF, Brown JP, Cosman F, Czerwiński E, et al. Relationship Between Bone Mineral Density T-Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment. *J Bone Miner Res.* 2019;34(6):1033–40.
20. Lamy O, Stoll D, Aubry-Rozier B, Rodriguez EG. Stopping Denosumab. *Curr Osteoporos Rep.* 2019;17(1):8–15.
21. Ramchand SK, David NL, Leder BZ, Tsai JN. Bone Mineral Density Response With Denosumab in Combination With Standard or High-Dose Teriparatide: The DATA-HD RCT. *J Clin Endocrinol Metab.* 2020;105(3).